Company profile
Interpace Biosciences, Inc.
OTC: IDXG · Healthcare · Medical - Diagnostics & Research
#471 of 1,418 Healthcare companies by revenue29th-percentile growth
EA Score
74BFH 83DQ 76GM 48SS 69
v0.1 · 65/100 weight · provisional
↑ return on equity, return on assets · ↓ revenue growth (YoY), growth stability
Methodology →Revenue TTM
$36.2M
Rev growth YoY (TTM)
-24.8%
Net income (FY)
$24.6M
Employees
102
as of 2026-08-20
Market cap
$43.5M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$38.7M$38.7M2025
Net income$24.6M$24.6M2025
Operating income$4.1M$4.1M2025
Total assets$33.8M$33.8M2025
Liabilities$11.5M$11.5M2025
Equity$22.4M$22.4M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY23
FY24
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Interpace Biosciences, Inc.’s revenue?
Interpace Biosciences, Inc. booked $38.7M in FY2025 revenue, contracting 17% year over year — slower than 71% of Healthcare companies we track, at a 63.5% net margin.
Peers · Healthcare
Enveric Biosciences, Inc.31DBig Tree Group, Inc.——Kymera Therapeutics, Inc.53DPalvella Therapeutics, Inc.54DUtah Medical Products, Inc.80B+Retractable Technologies, Inc.57CNeighbors
Morris →Key facts
CEOThomas W. Burnell
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersParsippany, NJ
ExchangeOTC: IDXG
Employees102
IPO date1998-05-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.